1 to 10 of 848
Sort by

35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020)

Same Location, NEW Days (Tuesday–Saturday in 2020) Thank You to Our Organizers Annual Program Committee CHAIR Sandra Demaria, MD – Weill Cornell Medicine 35 th Anniversary Annual Meeting Organizers Helen E. Heslop, MD – Baylor College of Medicine Brianna W. Hoffner, MSN, ANP-BC,...

 11-10-2020 08:00 - 11-14-2020 12:00 ET
 National Harbor MD

Web Page
Registration Rates

Interrogating the Tumor-Specific Surfaceome for Immune Targeting Workshop April 23-24, 2020 • San Diego Register Now Members of the Society for Immunotherapy of Cancer (SITC) are eligible for discounted registration rates to attend the 2020 SITC workshop on Interrogating the Tumor-Specific...

Library Entry
Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes

The role of tumor-infiltrating B-cells (TIBs) and intratumorally-produced antibodies in cancer-immunity interactions essentially remains terra incognita . In particular, it remains unexplored how driver mutations could be associated with distinct TIBs signatures and their role in tumor...

Library Entry
Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer

The treatment of endometrial cancer (EC), the most common gynecological cancer, is currently hampered by the toxicity of current cytotoxic agents, meaning novel therapeutic approaches are urgently required. The data the authors present, together with important design considerations implied by...

Library Entry
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma

Gene-modified autologous T cells expressing NY-ESO-1 c259 , an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1-specific HLA-A*02-restricted peptide SLLMWITQC (NY-ESO-1 SPEAR T-cells; GSK 794), have demonstrated clinical activity in patients with advanced synovial sarcoma ...

Library Entry
Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy

Immunotherapy using checkpoint inhibitors, especially PD-1/PD-L1 inhibitors, has now evolved into the most promising therapy for cancer patients. However, most of these inhibitors are monoclonal antibodies, and their large size may limit their tumor penetration, leading to suboptimal efficacy....

Library Entry
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies

Diffuse large B-cell lymphoma (DLBCL) harbors somatic hypermutation (SHM) in the immunoglobulin heavy chain and light chain variable region genes, IGHV and IGK/LV. Recent studies have revealed that IGV SHM creates neoantigens that activate T-cell responses against B-cell lymphoma. The authors...

Library Entry
Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer

The aim of this study is to profile the cytokines and immune cells of body fluid from metastatic gastric cancer (mGC), and evaluate the potential role as a prognostic factor and the feasibility as a predictive biomarker or monitoring source for immune checkpoint inhibitor. The authors conclude...

Library Entry
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial origin characterized by varying degrees of lymphocytic infiltration and a predisposition towards development of paraneoplastic autoimmunity. PD-1–targeting antibodies have been evaluated, largely in patients with thymic...

Library Entry
Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors

The interplay between the immune system and tumor progression is well recognized. However, current human breast cancer immunophenotyping studies are mostly focused on primary tumors with metastatic breast cancer lesions remaining largely understudied. To address this gap, the authors examined...